Asthma

>

Latest News

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma
Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

June 17th 2025

EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.

 Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma
Dupilumab Outperforms Omalizumab in First Head-to-Head Respiratory Study for CRSwNP with Comorbid Asthma

June 16th 2025

Half of Adults with Severe Asthma Treated with Tezepelumab Discontinue OCS Use at 52 Weeks: WAYFINDER / image credit Kings College London David J Jackson, MBBS, PhD
Half of Adults with Severe Asthma Treated with Tezepelumab Discontinue OCS Use at 52 Weeks: Phase 3b WAYFINDER Trial

May 22nd 2025

Dupilumab Improves Asthma Control, HRQoL Regardless of Comorbid Th2 Inflammatory Disease / image credit Adreanne Cote, MD, MSCE  Courtesy of Laval University
Dupilumab Improves Asthma Control, HRQoL Regardless of Comorbid Th2 Inflammatory Disease

May 21st 2025

Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma
Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma

May 8th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.